Đánh giá ban đầu điều trị ung thư vú tái phát di căn có thụ thể nội tiết dương tính HER-2 âm tính bằng fulvestrant tại Bệnh viện Đa khoa Đồng Nai

Patients with metastatic or recurrent metastatic breast cancer with hormone receptor-positive, receiving endocrine therapy with fulvestrant from January 2021 to October 2023 at Dong Nai General Hospital. Purpose: Results of initial treatment of metastatic or recurrent metastatic breast cancer that is hormone receptor-positive and Her2- negative with fulvestrant. Results: The average treatment time is 7.1 months. Patients are treated for at least 3 months, the longest is 25 months. Stable disease reaching the highest rate of 60%. There were 2 disease progression during treatment, one patient died due to acute liver failure. No case complete response. 3/15 patients partially respond. The progression-free survival time of our study group is 7 ± 1.54 months. Conclusions: Fulvestrant is an effective endocrine drug, early treatment should be considered in patients with breast cancer with metastatic recurrence, positive hormone receptors, low tumor burden. First-line treatment will be more effective than subsequent treatment steps.